Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
3,113
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma

Tomotaka Ugaia Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA;b Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USAView further author information
,
Melissa Zhaoa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Takashi Shimizuc Department of Cardiovascular Medicine, Graduate School of Medicine, the University of Tokyo, Tokyo, JapanView further author information
,
Naohiko Akimotoa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Shanshan Shia Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Yasutoshi Takashimaa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Rong Zhonga Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Mai Chan Laua Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Koichiro Harukia Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Kota Arimaa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Kenji Fujiyoshia Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Benjamin Langworthyb Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USAView further author information
,
Yohei Masugia Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Annacarolina da Silvaa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Katsuhiko Noshoa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Yoshifumi Babaa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Mingyang Songd Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA;e Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA;f Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USAView further author information
,
Andrew T. Chane Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA;f Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA;g Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA;h Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USAView further author information
,
Molin Wangb Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA;g Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA;i Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USAView further author information
,
Jeffrey A. Meyerhardtj Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USAView further author information
,
Marios Giannakisj Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA;k Broad Institute of MIT and Harvard, Cambridge, MA, USA;l Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Juha P. Väyrynena Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA;j Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA;m Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, FinlandORCID Iconhttps://orcid.org/0000-0002-8683-2996View further author information
ORCID Icon,
Jonathan A. Nowaka Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USAView further author information
&
Shuji Oginoa Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA;b Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA;k Broad Institute of MIT and Harvard, Cambridge, MA, USA;n Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber Harvard Cancer Center, Boston, MA, USACorrespondence[email protected]
View further author information
 show all
Article: 1956173 | Received 06 May 2021, Accepted 12 Jul 2021, Published online: 02 Aug 2021

References

  • Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, et al. PD-L2 expression in human tumors: relevance to Anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23(12):3158–11. doi:10.1158/1078-0432.CCR-16-1761.
  • Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhäuser M, Baretton G, Schmitz M. The evolving landscape of biomarkers for anti-PD-1 or ANTI-PD-L1 therapy. J Clin Med. 2019;8(10):1534.
  • Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76(2):227–238. doi:10.1158/0008-5472.CAN-14-3362.
  • Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361–370. doi:10.1158/2326-6066.CIR-13-0127.
  • Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013;19(3):598–609. doi:10.1158/1078-0432.CCR-12-2731.
  • Koveitypour Z, Panahi F, Vakilian M, Peymani M, Seyed Forootan F, Nasr Esfahani MH, Ghaedi K. Signaling pathways involved in colorectal cancer progression. Cell Biosci. 2019;9(1):97. doi:10.1186/s13578-019-0361-4.
  • Papadatos-Pastos D, Rabbie R, Ross P, Sarker D. The role of the PI3K pathway in colorectal cancer. Crit Rev Oncol Hematol. 2015;94(1):18–30. doi:10.1016/j.critrevonc.2014.12.006.
  • Cretella D, Digiacomo G, Giovannetti E, Cavazzoni A. PTEN Alterations As A Potential Mechanism For Tumor Cell Escape from PD-1/PD-L1 inhibition. Cancers (Basel). 2019;11(9):1318.
  • Molinari F, Frattini M. Functions and regulation of the PTEN gene in colorectal cancer. Front Oncol. 2013;3:326.
  • Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, Parry S, Jenkins MA, Win AK, Southey MC, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One. 2013;8(6):e65479. doi:10.1371/journal.pone.0065479.
  • Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61(6):847–854. doi:10.1136/gutjnl-2011-300865.
  • Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012;18(8):2257–2268. doi:10.1158/1078-0432.CCR-11-2410.
  • Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013;105(23):1789–1798. doi:10.1093/jnci/djt298.
  • Vogelaar FJ, Erning FNV, Reimers MS, Van Der Linden H, Pruijt H, Van Den Brule AJC, Bosscha K. The prognostic value of microsatellite instability, KRAS, BRAF and PIK3CA mutations in stage II colon cancer patients. Mol Med. 2016;21(1):1038–1046. doi:10.2119/molmed.2015.00220.
  • Mei ZB, Duan CY, Li CB, Cui L, Ogino S. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(10):1836–1848. doi:10.1093/annonc/mdw264.
  • Manceau G, Marisa L, Boige V, Duval A, Gaub M-P, Milano G, Selves J, Olschwang S, Jooste V, le Legrain M, et al. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. Cancer Med. 2015;4(3):371–382. doi:10.1002/cam4.370.
  • Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009;27(9):1477–1484. doi:10.1200/JCO.2008.18.6544.
  • Zumwalt TJ, Wodarz D, Komarova NL, Toden S, Turner J, Cardenas J, Burn J, Chan AT, Boland CR, Goel A, et al. Aspirin-Induced chemoprevention and response kinetics are enhanced by PIK3CA mutations in colorectal cancer cells. Cancer Prev Res (Phila). 2017;109(3):208–218. doi:10.1158/1940-6207.CAPR-16-0175.
  • Gu M, Nishihara R, Chen Y, Li W, Shi Y, Masugi Y, Hamada T, Kosumi K, Liu L, Da Silva A, et al. Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. Oncotarget. 2017;8(50):87379–87389. doi:10.18632/oncotarget.20972.
  • Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A. PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. a systematic review and meta-analysis of epidemiological studies. Clin Oncol (R Coll Radiol). 2016;28(5):317–326. doi:10.1016/j.clon.2015.11.008.
  • Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, Davidson B, Kerr DJ, Tomlinson IPM, Midgley R, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31(34):4297–4305. doi:10.1200/JCO.2013.50.0322.
  • Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596–1606. doi:10.1056/NEJMoa1207756.
  • Berntsson J, Eberhard J, Nodin B, Leandersson K, Larsson AH, Jirström K. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: relationship with sidedness and prognosis. Oncoimmunology. 2018;7:e1465165. doi:10.1080/2162402X.2018.1465165.
  • Masugi Y, Nishihara R, Hamada T, Song M, Da Silva A, Kosumi K, Gu M, Shi Y, Li W, Liu L, et al. Tumor PDCD1LG2 (PD-L2) expression and the lymphocytic reaction to colorectal cancer. Cancer Immunol Res. 2017;5(11):1046–1055. doi:10.1158/2326-6066.CIR-17-0122.
  • Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, Li Q, Cai S. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 2016;15(1):55. doi:10.1186/s12943-016-0539-x.
  • Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, Wang X, Timmons CL, Hu J, Liu B, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One. 2013;8(6):e65821. doi:10.1371/journal.pone.0065821.
  • Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer. 2013;49(9):2233–2242. doi:10.1016/j.ejca.2013.02.015.
  • Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, Song M, Mima K, Kosumi K, Liu L, et al. Aspirin use and colorectal cancer survival according to tumor CD274 (Programmed Cell Death 1 Ligand 1) expression status. J Clin Oncol. 2017;35(16):1836–1844. doi:10.1200/JCO.2016.70.7547.
  • Hutchinson L. Immunotherapy: evading immune escape: synergy of COX and immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2015;12:622.
  • Salvatore L, Calegari MA, Loupakis F,Fassan M, Di Stefano B, Bensi M, Bria E, Tortora G. PTEN in colorectal cancer: shedding light on its role as predictor and target. Cancers (Basel). 2019;11(11):1765.
  • Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, Simko JP, Waldman FM, Pieper RO, Parsa AT, et al. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene. 2009;28(2):306–312. doi:10.1038/onc.2008.384.
  • Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84–88. doi:10.1038/nm1517.
  • Oczko-Wojciechowska M, Pfeifer A, Jarzab M, Swierniak M, Rusinek D, Tyszkiewicz T, Kowalska M, Chmielik E, Zembala-Nozynska E, Czarniecka A, et al. Impact of the tumor microenvironment on the gene expression profile in papillary thyroid cancer. Pathobiology. 2020;87(Suppl. 2):143–154. doi:10.1159/000507223.
  • Gil J, Ramsey D, Pawlowski P, Szmida E, Leszczynski P, Bebenek M, Sasiadek MM. The influence of tumor microenvironment on ATG4D gene expression in colorectal cancer patients. Med Oncol. 2018;35(12):159. doi:10.1007/s12032-018-1220-6.
  • Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369(12):1095–1105. doi:10.1056/NEJMoa1301969.
  • Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009;15(20):6412–6420. doi:10.1158/1078-0432.CCR-09-1438.
  • Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S. Colorectal cancer: a tale of two sides or a continuum?: figure 1. Gut. 2012;61(6):794–797. doi:10.1136/gutjnl-2012-302014.
  • Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58(1):90–96. doi:10.1136/gut.2008.155473.
  • Irahara N, Nosho K, Baba Y, Shima K, Lindeman NI, Hazra A, Schernhammer ES, Hunter DJ, Fuchs CS, Ogino S. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn. 2010;12(2):177–183. doi:10.2353/jmoldx.2010.090106.
  • Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008;3(11):e3698. doi:10.1371/journal.pone.0003698.
  • Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006;8(2):209–217. doi:10.2353/jmoldx.2006.050135.
  • Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian Z, Liao X, Nishihara R, Jung S, Wu K, Nosho K, et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer. 2014;13(1):135. doi:10.1186/1476-4598-13-135.
  • Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005;7(3):413–421. doi:10.1016/S1525-1578(10)60571-5.
  • Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131–2142. doi:10.1056/NEJMoa067208.
  • Fujiyoshi K, Bruford EA, Mroz P, Sims CL, O'Leary TJ, Lo AWI, Chen N, Patel NR, et al. Opinion: standardizing gene product nomenclature-a call to action. Proc Natl Acad Sci U S A. 2021;118(3):e2025207118.
  • Masugi Y, Nishihara R, Yang J, Mima K, Da Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak JA, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017;66(8):1463–1473. doi:10.1136/gutjnl-2016-311421.
  • Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011;17(20):6563–6573. doi:10.1158/1078-0432.CCR-11-1244.
  • Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers EJ, Berk R, Bollen KA, Brembs B, Brown L, Camerer C, et al. Redefine statistical significance. Nat Hum Behav. 2018;2:6–10.
  • Haruki K, Kosumi K, Hamada T, Twombly TS, Väyrynen JP, Kim SA, Masugi Y, Qian ZR, Mima K, Baba Y, et al. Association of autophagy status with amount of fusobacterium nucleatum in colorectal cancer. J Pathol. 2020;250(4):397–408. doi:10.1002/path.5381.
  • Liu L, Nevo D, Nishihara R, Cao Y, Song M, Twombly TS, Chan AT, Giovannucci EL, VanderWeele TJ, Wang M, et al. Utility of inverse probability weighting in molecular pathological epidemiology. Eur J Epidemiol. 2018;33(4):381–392. doi:10.1007/s10654-017-0346-8.
  • Inaguma S, Lasota J, Wang Z, Felisiak-Golabek A, Ikeda H, Miettinen M. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol. 2017;30(2):278–285. doi:10.1038/modpathol.2016.185.
  • Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67(1):11–28. doi:10.1146/annurev-med-062913-051343.
  • Chida K, Kawazoe A, Kawazu M, Suzuki T, Nakamura Y, Nakatsura T, Kuwata T, Ueno T, Kuboki Y, Kotani D, et al. A low tumor mutational burden and PTEN mutations are predictors of a negative response to PD-1 blockade in MSI-H/dMMR gastrointestinal tumors. Clin Cancer Res. 2021;27(13):3714–3724. doi:10.1158/1078-0432.CCR-21-0401.
  • O’Donnell JS, Massi D, Teng MWL, Mandala M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin Cancer Biol. 2018;48:91–103. doi:10.1016/j.semcancer.2017.04.015.
  • Ni JM, Ni AP. Landscape of PD-1/PD-L1 regulation and targeted immunotherapy. Chin Med Sci J. 2018;33:174–182.
  • Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem. 2015;290(13):8110–8120. doi:10.1074/jbc.M114.612689.
  • Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6(2):202–216. doi:10.1158/2159-8290.CD-15-0283.
  • Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. doi:10.1158/2159-8290.CD-14-0863.
  • Bates SE, Longo DL. Epigenetic Therapies for Cancer. N Engl J Med. 2020;383(7):650–663. doi:10.1056/NEJMra1805035.
  • Akimoto N, Zhao M, Ugai T, Zhong R, Lau MC, Fujiyoshi K, Kishikawa J, Haruki K, Arima K, Twombly TS, et al. Tumor Long Interspersed Nucleotide Element-1 (LINE-1) hypomethylation in relation to age of colorectal cancer diagnosis and prognosis. Cancers (Basel). 2021;13:(9):2016.
  • Swets M, Zaalberg A, Boot A, van Wezel T, Frouws MA, Bastiaannet E, Gelderblom H, van de Velde CJ, Kuppen PJ. Tumor LINE-1 methylation level in association with survival of patients with stage II colon cancer. Int J Mol Sci. 2016;18(1):36.
  • Vedeld HM, Merok M, Jeanmougin M, Danielsen SA, Honne H, Presthus GK, Svindland A, Sjo OH, Hektoen M, Eknaes M, et al. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers. Int J Cancer. 2017;141(5):967–976. doi:10.1002/ijc.30796.
  • Levine AJ, Phipps AI, Baron JA, Buchanan DD, Ahnen DJ, Cohen SA, Lindor NM, Newcomb PA, Rosty C, Haile RW, et al. Clinicopathologic risk factor distributions for MLH1 promoter region methylation in CIMP-Positive tumors. Cancer Epidemiol Biomarkers Prev. 2016;25(1):68–75. doi:10.1158/1055-9965.EPI-15-0935.
  • Inamura K. Colorectal cancers: an update on their molecular pathology. Cancers (Basel). 2018;10(1):26.
  • Advani SM, Advani P, DeSantis SM, Brown D, VonVille HM, Lam M, Loree JM, Mehrvarz Sarshekeh A, Bressler J, Lopez DS, et al. Clinical, pathological, and molecular characteristics of CpG island methylator phenotype in colorectal cancer: a systematic review and meta-analysis. Transl Oncol. 2018;11(5):1188–1201. doi:10.1016/j.tranon.2018.07.008.
  • Tsai JH, Jeng YM, Yuan CT, Lin Y-L, Cheng M-L, Liau J-Y. Traditional serrated pathway-associated colorectal carcinoma: morphologic reappraisal of serrated morphology, tumor budding, and identification of frequent PTEN alterations. Am J Surg Pathol. 2019;43(8):1042–1051. doi:10.1097/PAS.0000000000001274.
  • Akimoto N, Ugai T, Zhong R, Hamada T, Fujiyoshi K, Giannakis M, Wu K, Cao Y, Ng K, Ogino S. Rising incidence of early-onset colorectal cancer — a call to action. Nat Rev Clin Oncol. 2021;18(4):230–243. doi:10.1038/s41571-020-00445-1.
  • Ogino S, Nowak JA, Hamada T, Milner DA, Nishihara R. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu Rev Pathol. 2019;14(1):83–103. doi:10.1146/annurev-pathmechdis-012418-012818.
  • Haruki K, Kosumi K, Li P, Arima K, Väyrynen JP, Lau MC, Twombly TS, Hamada T, Glickman JN, Fujiyoshi K, et al. An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer. Br J Cancer. 2020;122(9):1367–1377. doi:10.1038/s41416-020-0780-3.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.